Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 16, 2003BloodOpen Access

Rituximab for the treatment of refractory autoimmune hemolytic anemia in children

View Full Paper
Ask AI
Bookmark
Share

Authors

MZMarco ZeccaPoliclinico San Matteo Fondazione

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Marco Zecca (2003) studied this question.

synapsesocial.com/papers/6a9d2b9534685bd77029f575https://doi.org/10.1182/blood-2002-11-3547
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma2002 · 5,634 citations
  2. 2Prophylactic treatment with fresh‐frozen plasma in chronic thrombotic thrombocytopenic purpura2002 · 17 citations
  3. 3Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.1998 · 2,771 citations
  4. 4Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B‐cell lymphoma*2002 · 69 citations
  5. 5Anti‐CD20 monoclonal antibody (Rituximab) for life‐threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus2002 · 133 citations